Internalizing ErBB2 Antibodies
AssigneeThe Regents of the University of California
InventorsJames D. Marks, Marie Alix Poul
Life of this patent
Estimating the term…
Abstract
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Claims22
1-54. (canceled)
A method of delivering a chimeric molecule to a cancer cell bearing a c-erbB2 receptor, said chimeric molecule comprising an antibody that specifically binds to a c-erbB2 epitope as bound by F5 (as encoded by ATCC plasmid deposit designation PTA-7843) or C1 (SEQ ID NO:2) and is an internalizing antibody, wherein the antibody is coupled to a liposome comprising a therapeutic composition and the chimeric molecule is comprised by a pharmaceutical composition, wherein the pharmaceutical composition is administered to a patient suffering from a c-erbB-2 positive carcinoma.
A method of treating a disease that is a cancer, said method comprising administering a chimeric molecule to a patient suffering from a c-erbB-2 positive carcinoma, said chimeric molecule comprising an antibody that specifically binds to a c-erbB2 epitope as bound by F5 (as encoded by ATCC plasmid deposit designation PTA-7843) or C1 (SEQ ID NO:2) and is an internalizing antibody, wherein the antibody is coupled to a liposome comprising doxorubicin, said liposome bearing an external hydrophilic polymer that is a polyethylene glycol, and wherein the chimeric molecule is comprised by a pharmaceutical composition, wherein the pharmaceutical composition is administered as a therapeutically effective dose.
A method of delivering a chimeric molecule to a cancer cell, wherein the cancer cell is a carcinoma cell bearing a c-erbB2 receptor, said chimeric molecule comprising an internalizing antibody that specifically binds to a c-erbB2, said antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 1 having conservative substitutions, and SEQ ID NO:
- 2 having conservative substitutions, wherein the antibody is coupled to a liposome comprising doxorubicin, said liposome bearing an external hydrophilic polymer that is a polyethylene glycol, and wherein the chimeric molecule is comprised by a pharmaceutical composition, wherein the method comprises administering the pharmaceutical composition to a patient suffering from a metastatic or solid tumor of a c-erbB-2 positive carcinoma.
Dependencies are inferred from the claim text.